Vol. 22/No. 11 | OncologyLive

CD20-Targeting Antibodies Are Shaping a New Landscape for B-Cell Cancers

June 16, 2021

Among the pioneering targets for antibody therapy was CD20, the pursuit of which ultimately led to the first FDA-approved mAb for cancer therapy, rituximab, and defined a new era in the management of B-cell malignancies.

Investigators Set Sights on Curative Approaches for Follicular Lymphoma

June 15, 2021

The majority of patients with indolent follicular lymphoma do well with observation and after first-line treatment, but approximately 20% experience disease progression within 2 years of their initial treatment, which is associated with a 50% risk of dying within 5 years. Subsequently, this is an area of unmet need but one in which considerable progress is being made.

The Next Chapter in RCC Recontextualizes Treatment Considerations

June 15, 2021

Renal cell carcinoma is one of the top 10 most common cancers, although incidence rates have been stable over the past decade. It is more common in men than women and rates are higher among African American, American Indian, and Alaska Native patient populations.

The US Oncology Network Highlights Success With Oncology Care Model

June 10, 2021

Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.

Novel Combination Holds Potential to Address All Hallmarks of Myelofibrosis

June 10, 2021

In an effort to build on the efficacy demonstrated with ruxolitinib, investigators are evaluating combination therapies—specifically the dual inhibition of the JAK-STAT and BET pathways using pelabresib, a novel BET inhibitor.

Loncastuximab Tesirine Provides Alternative for Broad Range of Patients With DLBCL

June 01, 2021

Loncastuximab tesirine-lpyl (Zynlonta) exhibited significant clinical activity, including impressive response rates with tolerable safety, as a single agent in adult patients with relapsed/refractory large B-cell lymphoma that failed prior established therapies.

COVID-19 Vaccination Hesitancy Finds Echo in Cancer Care

June 01, 2021

From the Editor

Although the COVID-19 vaccine rollout is unprecedented in speed and scope, the process of postapproval surveillance has been shown to be robust and should serve as a source of reassurance to the public regarding the effectiveness of the initial and follow-up review process.